Catalyst Dossier · compiled by CeliA 🧫

OPKO HEALTH, INC. (OPK)

Pharmaceutical Preparations · market cap $1.1B

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-30

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-07-30Earningsimp 5/10

Pipeline

Asset	Phase	Indication
LY2944876	Phase 2	Diabetes Mellitus, Type 2
TT223 with Metformin and/or TZD	Phase 2	Diabetes Mellitus, Type 2
Genotropin	Phase 3	Growth Hormone Deficiency
OPK-88003	Phase 2	Type 2 Diabetes Mellitus
ELND005 (scyllo-inositol)	Phase 2	Alzheimer's Disease
ELND005	Phase 2	Alzheimer's Disease
bevasiranib	Phase 2	Diabetic Macular Edema
CTAP101 Capsules	Phase 3	Chronic Kidney Disease
MOD-4023	Phase 3	Pediatric Growth Hormone Deficiency
CTA018 cream	Phase 2	Psoriasis
Rayaldee	Phase 2	COVID-19
Cohort 1 CTAP101 Capsules- 60µg	Phase 3	Chronic Kidney Disease
Somatropin	Phase 3	Pediatric Growth Hormone Deficiency
MDX2003	Phase 2	Lymphoma
CTAP101 30 μg capsules	Phase 3	Chronic Kidney Disease
MDX2004	Phase 2	Advanced Tumors
MDX2001	Phase 2	Biliary Tract Cancer
CTA018 Injection	Phase 2	Chronic Kidney Disease

Price & technical context

3-month

+34.5%

6-month

+16.9%

12-month

+14.3%

52-wk range

$1.10–$1.58

vs 50-day MA

+15.9%

vs 200-day MA

+15.9%

Realized vol

37.3%

Max drawdown

-43.3%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for OPK (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 18 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.